Charlotte Robinson

DocwireNews

APPLAUSE-IgAN is a phase 3 study to determine the efficacy and safety of iptacopan versus placebo in patients with IgA nephropathy (IgAN). <a href="https://www.docwirenews.com/post/applause-igan-findings-presented-at-nkf-spring-clinical-meetings">Dana V. Rizk </a>and fellow researchers presented prespecified interim analysis (IA) results of the study during the National Kidney Foundation Spring Clinical Meetings.The randomized, double-blind, placebo-controlled study evaluates iptacopan plus optimized supportive care in patients with biopsy-confirmed IgAN and proteinuria &ge;1 g/g by urine protein-to-creatinine ratio (UPCR) from 24-hour urine collection (UPCR-24h) despite maximally tolerated renin-angiotensin system inhibitors for &ge;3 months. The researchers randomized patients 1:1 to receive iptacopan 200 mg or placebo twice daily for 24 months.At the prespecified IA, researchers evaluated 125 patients for iptacopan and 125 patients for placebo. The safety analyses included 222 patients for iptacopan and 221 for placebo. The baseline characteristics were balanced across treatment arms.Iptacopan proved superior to placebo in reducing proteinuria (UPCR-24h) from baseline at month 9 (M9), with a reduction of 38.3% (95% CI, 26.0%-48.6%; one-sided P&lt;.0001) versus placebo. UPCR from first morning void declined as early as week 2; the reduction from baseline at M9 with iptacopan versus placebo was 35.8% (95% CI, 22.6%-46.7%).About twice as many patients on iptacopan reached UPCR-24h &lt;1 g/g at M9 compared with the placebo group (marginal proportion, 42.5% [95% CI, 34.5%-50.5%] vs 21.9% [95% CI, 14.8%-29.0%], respectively). Adverse events prevented 2.7% of patients in each group from completing treatment. Otherwise, iptacopan was well tolerated with an infection rate not exceeding that of the placebo group.The authors concluded that &ldquo;APPLAUSE-IgAN demonstrated superiority of iptacopan versus placebo in proteinuria reduction at M9, with early onset and consistency of effect. Iptacopan was well tolerated with a favorable safety profile.&rdquo;Source: Rizk DV, Kollins D, Papachristofi O, et al. <a href="https://cme.kidney.org/spa/courses/resource/2024-spring-clinical-meetings/event/home/posters/abstracts?abstractId=5162" target="_blank" rel="noopener">Efficacy and safety of iptacopan in patients with IgA nephropathy (IgAN): interim analysis (IA) of the phase 3 APPLAUSE-IgAN study.</a> Presented at the National Kidney Foundation Spring Clinical Meetings 2024; May 14-18, 2024; Long Beach, California.

Jordana Jampel

Positive Preliminary Results From Phase 1 Trial of Dopaminergic Neuron Graft for Parkinson’s Disease

Dementia

Bradley Warady, MD

Joel M. Topf, MD, FACP

2025 Hume Award Winner Is Dedicated to Children’s Care

NKF Spring Clinical Meetings 2025

Distant Brain Metastases in Cutaneous Melanoma May Be Mitigated With Multiple Pathway Inhibitors

Melanoma

Latest News

Interim Analysis of APPLAUSE-IgAN Iptacopan Study

NKF Spring Clinical Meetings 2024

The APPLAUSE-IgAN study evaluated iptacopan plus supportive care in patients with IgA nephropathy (IgAN). The phase 3 study examined the drug's safety and efficacy. 

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe